- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Nanogen, Inc. (Nasdaq:NGEN), developer of innovative, high-quality diagnostic products, will host a conference call on Thursday, March 13, 2008 at 4:30 p.m. Eastern (1:30 p.m. Pacific) to discuss 2007 fourth quarter and full year financial results. The financial results press release will be issued at market closing on March 13, 2008. Interested investors and others may participate in the conference call by dialing 800.435.1261 for US/Canada participants and 617.614.4076 for international participants. The conference ID will be 29699739.
Audio of management's presentation will be available via live webcast on the investor relations section of Nanogen's corporate website at www.nanogen.com, and will be archived for one year. A digital recording of the call will also be available for 48 hours, beginning two hours after the completion of the conference call on March 13, and can be accessed via telephone at 888-286-8010 for US/Canada participants and 617-801-6888 for international participants. The conference ID, 98585032, will be required to listen to the playback.
About Nanogen, Inc.
Nanogen (Nasdaq:NGEN) has a strong product and proprietary technology base of diagnostic solutions for two of the fastest growing in vitro diagnostic (IVD) markets—molecular diagnostics and rapid point-of-care testing. The company provides their innovative, high-quality diagnostic products to clinicians and physicians worldwide, making it easier to predict and diagnose diseases, ultimately improving patient care. Products include molecular diagnostic kits and reagents, and kits for rapid, point-of-care testing. Nanogen has pioneered research in areas involving biomedical markers, molecular biology and nanotechnology to bring better results to diagnostics and healthcare. For additional information please visit Nanogen’s website at www.nanogen.com.
Nanogen Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements, including whether patents owned or licensed by Nanogen will be developed into products, whether the patents owned by Nanogen offer any protection against competitors with competing technologies, whether products under development can be successfully developed and commercialized, whether results reported by our customers or partners can be identically replicated, and other risks and uncertainties discussed under the caption "Factors That May Affect Results" and elsewhere in Nanogen’s Form 10-K or Form 10-Q most recently filed with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Nanogen disclaims any intent or obligation to update these forward-looking statements.
For more information, please click here
Nicholas Venuto, Chief Financial Officer
Kelly Gann, Marketing Communications
Copyright © Business Wire 2008If you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Artificial synapse rivals biological ones in energy consumption June 21st, 2016
Nanometrics Announces Upcoming Investor Events May 10th, 2016
Call for NanoArt and Art-Science-Technology Papers June 9th, 2016
Novel gene therapy shows potential for lung repair in asthma May 18th, 2016